CHINA PHARMA HOLDINGS, INC. Stock or Unit Option Plan Expense
CHINA PHARMA HOLDINGS, INC. (CPHI) reported Stock or Unit Option Plan Expense of $78.27 thousand for the 12-month period ending 2022-12-31, per its 10-K filed 2024-04-01.
Discontinued › Cash Flow › Other Cash Flow Items
us-gaap:StockOptionPlanExpense · last filed 2024-04-01
- CHINA PHARMA HOLDINGS, INC. stock or unit option plan expense for the quarter ending 2021-12-31 was $0.00.
- CHINA PHARMA HOLDINGS, INC. stock or unit option plan expense for fiscal 2022 was $78.27K, a 413.48% increase from fiscal 2021.
- CHINA PHARMA HOLDINGS, INC. stock or unit option plan expense for fiscal 2021 was $15.24K.
| Period end | Stock or Unit Option Plan Expense 3 month | Stock or Unit Option Plan Expense 9 month | Stock or Unit Option Plan Expense 12 month |
|---|---|---|---|
| 2022-12-31 | $78.27K 10-K · filed 2024-04-01 | ||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | $15.24K 10-K · filed 2023-03-30 | |
| 2021-09-30 | $15.24K 10-Q · filed 2021-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NANOVIRICIDES, INC. (NNVC) | United States | $0.031B | |
| Propanc Biopharma, Inc. (PPCB) | $0.032B | -0.13 | |
| BeyondSpring Inc. (BYSI) | United States | $0.031B | -10.95 |
| Context Therapeutics Inc. (CNTX) | United States | $0.034B | -1.10 |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| ROCKWELL MEDICAL, INC. (RMTI) | United States | $0.035B | |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |